Skip to main content

Xavier Martínez Gómez

Institutions of which they are part

Epidemiology and Public Health
Vall Hebron Institut de Recerca

Xavier Martínez Gómez

Institutions of which they are part

Epidemiology and Public Health
Vall Hebron Institut de Recerca

Research lines

Vaccines

The group has participated in different phase II, III and IV clinical trials focused on the study of the immunogenicity, efficacy and safety of several preventive vaccines (e.g. influenza, human papilloma virus, hepatitis B, herpes zoster, respiratory syncytial virus…).

Currently, our group has expanded its line of research on the adjuvanted recombinant Herpes Zoster vaccine testing its safety and immunogenicity in pediatric immunosuppressed patients and adults =50 years of age with a prior episode of Herpes Zoster. Regarding observational studies, the group is leading a population study about the incidence of herpes zoster by risk groups (PI15/02273).

Our team has also started a new line of investigation for a Respiratory Syncytial Virus vaccine in healthy pregnant women.

IP: Xavier Martínez Gómez

Projects

ESTUDIO DEL PAPEL DE LA CENTRALIZACIÓN DEL DIAGNÓSTICO ANATOMOPATOLÓGICO Y LA APLICACIÓN DE ESTRATÉGIAS DE MEDICINA DE PRECISIÓN EN SARCOMAS

IP: Cleofé Romagosa Pérez-Portabell
Collaborators: Xavier Martínez Gómez, Ximena Garcia Torres
Funding agency: Asociación Española Contra el Cáncer
Funding: 270130
Reference: ECAEC222952DEAL
Duration: 01/12/2022 - 30/11/2027

INCIDENCIA Y HOSPITALIZACIÓN POR HERPES ZÓSTER EN CATALUÑA ENTRE 2007 Y 2017

IP: Magda Campins Martí
Collaborators: Xavier Martínez Gómez, Sonia Maria Uriona Tuma, Sonia Maria Uriona Tuma
Funding agency: Instituto de Salud Carlos III
Funding: 24926
Reference: PI15/02273
Duration: 01/01/2016 - 30/11/2020

Development of a universal inFLUenza vaccine based on Tandem CORE technology (FLUTCORE) Grant Agreement nº 602437

IP: Magda Campins Martí
Collaborators: Jose Angel Rodrigo Pendás, Susana Otero Romero, Xavier Martínez Gómez, Tomàs Pumarola Suñé, Sonia Maria Uriona Tuma, Sonia Maria Uriona Tuma
Funding agency: EUROPEAN COMMISSION
Funding: 81420
Reference: FLUTCORE_FP7HEALTH2013
Duration: 01/09/2013 - 31/03/2017

Aticuerpos antitransglutaminasa en biopsias musculares de pacientes con miopía inflamatoria

IP: Albert Selva O'Callaghan
Collaborators: Moisés Labrador Horrillo, Ernesto Trallero Araguas, Xavier Martínez Gómez
Funding agency: Instituto de Salud Carlos III
Funding: 33880
Reference: PI080450
Duration: 01/01/2009 - 31/12/2011

Related news

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.

A l'estudi hi participaran 200 persones voluntàries i es durà a terme a 10 hospitals espanyols, entre els quals Vall d’Hebron.

Related professionals

Lourdes Zamorano Moreno

Lourdes Zamorano Moreno

Zelador/a
General Services and Infrastructure
Manager
Read more
Mónica Pamies Serrano

Mónica Pamies Serrano

Biomedical Research in Gynaecology
Read more
Daniel Eiroa Gutierrez

Daniel Eiroa Gutierrez

Research technician
Molecular Medical Imaging
Read more
Anna Suades Juncadella

Anna Suades Juncadella

Research technician
Neurovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.